Piper Sandler analyst David Westenberg raised the firm’s price target on Idexx Laboratories to $600 from $525 and keeps a Neutral rating on the shares. The firm cites the company’s recent earnings release.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDXX:
- Idexx Laboratories price target raised to $620 from $600 at Morgan Stanley
- Idexx Laboratories price target raised to $570 from $525 at Stifel
- Idexx Laboratories price target raised to $655 from $605 at Barclays
- Early notable gainers among liquid option names on February 5th
- Idexx Laboratories sees 2024 EPS $10.84-$11.33, consensus $11.00
